左甲状腺素对老年亚临床甲减心血管影响的模拟目标试验
基于英国THIN数据库的观察性模拟目标试验,纳入22621例50岁以上亚临床甲减患者,比较左甲状腺素治疗与未治疗者10年结局。左甲状腺素与心血管事件(aHR 0.82)和全因死亡(aHR 0.71)风险降低相关,骨事件无显著增加,心血管获益仅限于促甲状腺素高于年龄特异性范围且治疗至少5年的患者。
要点
- 老年亚临床甲减患者使用左甲状腺素与心血管事件和全因死亡风险降低相关
- 骨事件风险未见显著增加(aHR 1.04)
- 心血管获益仅限于促甲状腺素高于年龄特异性范围且治疗≥5年者
核心结论
- 长期左甲状腺素治疗与老年亚临床甲减患者较低的心血管事件和全因死亡风险相关,且对骨健康无显著危害。
- 年龄特异性促甲状腺素水平应指导治疗决策。
研究设计与样本
- 观察性模拟目标试验,使用英国健康改善网络(THIN)数据。
- 纳入22621例50岁以上亚临床甲减患者(促甲状腺素4.1-10.0mU/L,游离甲状腺素10.0-24.0 pmol/L),中位年龄66岁,76.7%为女性。
- 62%接受左甲状腺素治疗,38%未接受;采用逆概率治疗加权(IPTW)调整年龄、性别、BMI、Charlson合并症指数、总胆固醇、高血压、促甲状腺素、激素药物和吸烟。
主要发现
- 心血管获益仅限于促甲状腺素水平高于年龄特异性范围的患者,且需至少5年治疗。
关键数值与推荐
- 亚临床甲减定义:促甲状腺素4.1-10.0mU/L,游离甲状腺素10.0-24.0 pmol/L。
- 主要结局为心血管事件(心绞痛、心肌梗死、外周血管病、支架手术或卒中)。
- 次要结局包括骨事件(脆性骨折或骨质疏松)和全因死亡。
临床怎么用
- 对老年亚临床甲减患者,应参考年龄特异性促甲状腺素范围评估治疗指征。
- 促甲状腺素高于年龄特异性范围者可能从长期左甲状腺素治疗中获得心血管和生存获益。
- 治疗决策时需权衡长期(≥5年)获益与潜在风险,骨健康方面未见显著危害。
局限性
- 观察性模拟目标试验设计,可能存在未测量混杂。
- 数据来源为英国THIN数据库,外推性需谨慎。
- 亚临床甲减诊断基于促甲状腺素4.1-10.0mU/L,未涵盖更高水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyrotropin levels increase with age, but standard reference intervals do not account for this, potentially leading to overdiagnosis of subclinical hypothyroidism (SCH) and overuse of levothyroxine in older adults. METHODS: Using data from The Health Improvement Network, this observational emulated target trial study assessed 10-year outcomes in adults over 50 years with SCH (thyrotropin 4.1-10.0mU/L, free thyroxine 10.0-24.0 pmol/L) who were prescribed levothyroxine versus those who were not. Subgroup analyses were limited to patients with age-specific thyrotropin levels. The primary outcome was cardiovascular events (angina, myocardial infarction, peripheral vascular disease, stent procedures, or stroke). Secondary outcomes included bone events (fragility fractures or osteoporosis) and all-cause mortality. Hazard ratios, adjusted through inverse probability of treatment weighting (IPTW) for age, sex assigned at birth, body mass index, Charlson comorbidity index, total cholesterol, hypertension, thyrotropin, hormonal medications, and smoking, were estimated. FINDINGS: Between January 1, 2006, and January 1, 2022, 22,621 patients (median age [interquartile range]: 66 [59-75] years, 76.7% female) were identified; 62% received levothyroxine and 38% did not. Levothyroxine was associated with reduced cardiovascular (IPTW-adjusted hazard ratio [aHR]: 0.82; CI: 0.74-0.91; p < 0.0001) and all-cause mortality (aHR: 0.71; CI: 0.67-0.75; p < 0.0001), with no adverse effects on bone (aHR: 1.04; CI: 0.93-1.17; p = 0.45). Cardiovascular benefits were limited to patients with thyrotropin levels above the age-specific range and after at least five years of treatment. INTERPRETATION: Long-term levothyroxine use in older adults with SCH was associated with lower long-term cardiovascular and all-cause mortality risks, with no significant harm to bone health. Age-specific thyrotropin levels should guide treatment decisions.
引用
- Holley M, Razvi S, Maxwell I, et al. Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing UK Population with Subclinical Hypothyroidism: Emulated Target Trial (ACEL-UK-ETT). Thyroid. 2026. PMID: 41712269. doi:10.1177/10507256261426576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。